CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActive® technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.
Company Growth (employees)
Type
Private
HQ
Tübingen, DE
Founded
2000
Size (employees)
145 (est)
CureVac was founded in 2000 and is headquartered in Tübingen, DE

Key People/Management at CureVac

Ingmar Hoerr

Ingmar Hoerr

Chief Executive Officer
Mathias Hothum

Mathias Hothum

Baord of Directors
Franz-Werner Haas

Franz-Werner Haas

Chief Corporate Officer
Ulrike Gnad-Vogt

Ulrike Gnad-Vogt

Acting Chief Medical Officer
Mariola Fotin-Mleczek

Mariola Fotin-Mleczek

Acting Chief Scientific Officer

CureVac Office Locations

CureVac has offices in Tübingen, Frankfurt am Main and Boston
Tübingen, DE (HQ)
Paul-Ehrlich-Str. 15
Boston, US
51 Melcher St
Frankfurt am Main, DE
27 Schumannstraße
Tübingen, DE
15 Paul-Ehrlich-Straße

CureVac Financials and Metrics

Summary Metrics

CureVac's latest funding round in November 2016 was reported to be $29.5 m. In total, CureVac has raised $359 m. CureVac's latest valuation is reported to be $1.7 b.

CureVac Financials

USD

Market valuation

1.7 b
Show all financial metrics

Traffic Overview of CureVac

CureVac Online and Social Media Presence

CureVac News and Updates

Pharma’s Future: 100+ Startups Working Across Alzheimer’s, Diabetes, Cancer, And More

The pharmaceutical industry is changing at a rapid pace. The introduction of immunotherapy techniques such as CAR-T cell therapy and cancer vaccines are bringing oncology into the 21st century while CRISPR is poised to bring genetic editing into every clinic … Continued

CureVac Company Life and Culture

You may also be interested in